11th Annual Oncology Innovation Forum

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

10th of January 2026|MARINES' MEMORIAL CLUB | SAN FRANCISCO | USA
Sachs Associates would like to say we enjoyed hosting you at our 11th Annual Oncology Innovation Forum (#Sachs_OIF). We would like to thank those who joined us in-person in San Francisco and those who participated virtually last week. A special thank you goes to the excellent lineup of sponsors, chairs, panellists, and presenters who made such a broad and interesting programme possible. The programme highlighted continued progress in cancer treatment and related investor opportunities, with nearly 300 participants registered from 19 countries. To view photos from the event, please navigate to the 'PHOTOS’ tab. To watch a session on-demand, please navigate to the 'RECORDINGS' tab and select the panel or session you want to view. To view showcases, please click on the 'PRESENTERS' tab. Each company will have a showcase button, which will allow you to view their presentation. The Online Meeting System and event portal will be available for review, messaging people and exchanging contacts with people you did not have a chance to meet until the 11th of February 2026. We look forward to welcoming you again to our future events!

CONTRIBUTING SPONSOR:

Davis Polk & Wardwell LLP

Presenting Companies Included:

7 Hills Pharma Inc. logo
Accession Therapeutics Ltd. logo
Ascensus Therapeutics, Inc. logo
Biomunex Pharmaceuticals logo
Biond Biologics Ltd. logo
Cullinan Therapeutics, Inc. logo
Laverock Therapeutics Ltd. logo
NEOK Bio, Inc. logo
OxSonics logo
Toray Industries, Inc. logo
Vitarka Therapeutics Ltd logo

Confirmed Keynote Speakers Included:

AN
Aditya Natarajan
Managing Director, L.E.K. Consulting LLC

Speakers and Chairs Included:

BA
Biren Amin
Managing Director, Healthcare Equity Research, Piper Sandler & Co.
Evonne Sepsis
Evonne Sepsis
Managing Director, ESC Advisors
Jay Olson
Jay Olson
Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
Jeff Jones
Jeff Jones
Managing Director & Senior Analyst, Oppenheimer & Co. Inc.
Joel Sandler
Joel Sandler
Associate Partner, Ipsos Healthcare Advisory Service
JN
John Newman
Analyst - Biotechnology, Canaccord Genuity
Kaveri Pohlman
Kaveri Pohlman
Managing Director - Senior Research Analyst, Clear Street LLC
MK
Michael Kingston
Managing Director, Global Co-Head of Biopharma & Co-Head of North American Healthcare, Lazard Ltd.
Michael Rice
Michael Rice
Expert Advisor, SVP, Cell & Gene Therapy, Lumanity
PS
Peter Sandor
EVP Head of Corporate Strategy, Astellas Pharma, Inc.
Steve Dickman
Steve Dickman
CEO, CBT Advisors
Viraj Parekh
Viraj Parekh
Vice President, Oncology Lead, Lumanity
Anna Karmann
Anna Karmann
Chief Medical Officer, AdvanCell Pty Ltd.
Ben Hickey
Ben Hickey
President, RayzeBio, Inc.
Blaine Robinson
Blaine Robinson
VP, Therapy Acceleration Program, Blood Cancer United
Chris Williams
Chris Williams
CBO, Autolus Therapeutics PLC
Christopher Heery
Christopher Heery
Chief Medical Officer, Arcellx, Inc.
Daniel Teper
Daniel Teper
Founder & CEO, NAYA Therapeutics
David Bauer
David Bauer
Partner, Head of Life Sciences, Davis Polk & Wardwell LLP
David Chacko
David Chacko
CFO & CBO, Erasca, Inc.
David G. Benathan
David G. Benathan
VP, Head BD&L Transactions Oncology & RLT, Novartis Pharma AG
Dominic McDonald
Dominic McDonald
Executive Director, Search & Evaluation (Oncology) R&D Business Development, GSK
DA
Dozie Amuzie
Senior Director, Oncology Scientific Innovation & Partnerships, Johnson & Johnson Innovation LLC
Duncan Young
Duncan Young
Head of Search & Evaluation, Business Development, Oncology, AstraZeneca
Fiona MacLaughlin
Fiona MacLaughlin
Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.
Geoff Towle
Geoff Towle
Therapeutic Area Strategy Head, RLT, Novartis AG
Gregor Fachinger
Gregor Fachinger
VP, Head of Oncology & Immuno-Oncology Business Development, Merck KGaA, Darmstadt, Germany
Jack Hoppin
Jack Hoppin
Co-Founder, CEO & Chairman, Ratio Therapeutics
Jez Gerry
Jez Gerry
COO & Head of Preclinical Development, Accession Therapeutics Ltd.
John Flygare
John Flygare
Head of Large Molecule Innovation, Eli Lilly and Company
Lori Lyons-Williams
Lori Lyons-Williams
President & CEO, Abdera Therapeutics
Lucas Donigian
Lucas Donigian
VP, Business & Commercial Development, Zymeworks Inc.
Mayank Gandhi
Mayank Gandhi
CEO, NEOK Bio, Inc.
Michael Salgaller
Michael Salgaller
Supervisory Specialist, National Institutes of Health (NIH)
MC
Moitreyee Chatterjee-Kishore
Head, Oncology Development, Astellas Pharma, Inc.
Nadim Ahmed
Nadim Ahmed
President & CEO, Cullinan Therapeutics, Inc.
Nina Shah
Nina Shah
Executive Director, Global Head of Multiple Myeloma Clinical Development & Strategy, AstraZeneca
Norbert Prenzel
Norbert Prenzel
Head of BD & Licensing, SOTIO Biotech a.s.
Palani Palaniappan
Palani Palaniappan
Chief Technical Operations Officer, Flagship Pioneering
PT
Pascal Touchon
Operating Partner, Jeito Capital
Paul Higham
Paul Higham
CEO, Pathios Therapeutics Ltd.
Philipp Spycher
Philipp Spycher
Co-Founder & CSO, Araris Biotech AG
Raven Lin
Raven Lin
Co-Founder & CEO, Pilatus Biosciences SA
Regina Salvat
Regina Salvat
Principal, Forbion
Stefanie Flückiger-Mangual
Stefanie Flückiger-Mangual
Co-Founder & CEO, TOLREMO Therapeutics AG
Stephanie Oestreich
Stephanie Oestreich
Managing Director, Myeloma Investment Fund (MIF)
Thijs Spoor
Thijs Spoor
CEO, Perspective Therapeutics
Upendra Marathi
Upendra Marathi
President & CEO, 7 Hills Pharma Inc.
Yosef Refaeli
Yosef Refaeli
CEO, Ascensus Therapeutics, Inc.

SACHS ASSOCIATES SWITZERLAND AG

Aeschenvorstadt 4
Basel | CH-4051
Switzerland

SACHS ASSOCIATES LTD.

3rd floor, 89-90 Paul Street
London | EC2A 4NE
United Kingdom
Privacy Policy

© COPYRIGHT 2026. ALL RIGHTS RESERVED.